Data compiled by Redley Lamar · ChainSifter Intelligence
5Suppliers
10Customers
3Debt Items
20Related Chains
Source-Backed Evidence Depth
Oramed Pharmaceuticals Inc. (ORMP) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
19Total relationships
3Distinct source URLs
10High confidence
0.800Average confidence
2026-09-13Latest database update
ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.
At the Notes Closing, Lifeward issued to the Company (i) $9,000,000.00 aggregate principal amount of the Notes with an initial conversion price equal to $5.40 per share
Reciprocal relationship from LFWD graph: Reciprocal relationship from ORMP graph: At the Notes Closing, Lifeward issued to the Company (i) $9,000,000.00 aggregate principal amount of the Notes with a…
Pursuant to the Warrant Agreement, the Company deferred its right to receive an amortization payment scheduled to be paid by Scilex on October 1, 2025 as set forth in the amortization schedule includ…
Reciprocal relationship from SCLX graph: Reciprocal relationship from ORMP graph: Reciprocal relationship from SCLX graph: Reciprocal relationship from ORMP graph: Reciprocal relationship from SCLX g…
Reciprocal relationship from SMNR graph: o other available therapies. Health Technology Assessment (“HTA”) of medicinal products is becoming an increasingly common part of the pricing and reimburseme…
Reciprocal relationship from LFWD graph: Reciprocal relationship from ORMP graph: Reciprocal relationship from LFWD graph: Proposal No. 1: To approve the Company's issuance of Ordinary Shares, as des…
Reciprocal relationship from SCLX graph: Pursuant to the Warrant Agreement, Oramed deferred its right to receive an amortization payment scheduled to be paid by the Company on October 1, 2025 as set …
Reciprocal relationship from NNDM graph: Reciprocal relationship from ORMP graph: the scope of ASC 323. These warrants are measured at fair value, with changes in fair value recognized in “Financial …
the scope of ASC 323. These warrants are measured at fair value, with changes in fair value recognized in “Financial income (loss), net” in the consolidated statements of operations. 4. Lifeward Reve…
Reciprocal relationship from PTHS graph: Reciprocal relationship from ORMP graph: the scope of ASC 323. These warrants are measured at fair value, with changes in fair value recognized in “Financial …
the scope of ASC 323. These warrants are measured at fair value, with changes in fair value recognized in “Financial income (loss), net” in the consolidated statements of operations. 4. Lifeward Reve…
ALPHA-TAU-MEDICAL-LTD
ALPHA-TAU-MEDICAL-LTD
62%
ce providers to assist us with the execution of our clinical trials. Clinical activities, which relate principally to clinical sites and other administrative functions to manage our clinical trials, …
ENTERA-BIO-LTD
ENTERA-BIO-LTD
62%
the scope of ASC 323. These warrants are measured at fair value, with changes in fair value recognized in “Financial income (loss), net” in the consolidated statements of operations. 4. Lifeward Reve…
MEDICOX-CO-LTD
MEDICOX-CO-LTD
62%
ce providers to assist us with the execution of our clinical trials. Clinical activities, which relate principally to clinical sites and other administrative functions to manage our clinical trials, …
ORATECH-LTD
ORATECH-LTD
62%
mpany transferred to OraTech Ltd. all intellectual property and related assets relating to the Company’s POD™ (Protein Oral Delivery) technology platform, together with $ 6,500 to fund the next plann…
Oramed Pharmaceuticals Inc. Debt Obligations
Instrument
Description
Confidence
Evidence
ORMP-DEBT-11593
Warrants outstanding: 20000
90%
xbrl warrant detail from xbrl 2025-12-31.
ORMP-DEBT
Debt stack $106.6M
90%
Market cache reports total debt of $106.6M.
ORMP-DEBT-11594
Xbrl Convertible
90%
xbrl convertible detail from xbrl 2013-08-31.
Oramed Pharmaceuticals Inc. Acquisitions
No acquisitions on recordNo completed or pending acquisitions found in our database for Oramed Pharmaceuticals Inc..
Oramed Pharmaceuticals Inc. Ownership
Holder
Name
Confidence
Evidence
ORMP-OWNER-VANGUARD-CAPITAL-MANAGEMENT-LLC
VANGUARD CAPITAL MANAGEMENT LLC
90%
13F overlay lists VANGUARD CAPITAL MANAGEMENT LLC as top holder; 72 tracked holders.
Oramed Pharmaceuticals Inc. Extended Supply Chain Network
